10 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 6 Phase 2, 5 Phase 1, 3 Phase 4, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 4 | 3 | Recruiting 3 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Insulin-Like Growth Factor I, Resistance To: new trials by email Literature Review of Insulin-Like Growth Factor I, Resistance To trials Research Report on Insulin-Like Growth Factor I, Resistance To
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO IBI311, Follew-up - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 50 | 2025-04-15 | 2025-09-03 |
| Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 96 | 2025-04-15 | 2025-09-03 |
| The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 64 | 2025-04-10 | 2025-09-03 |
| Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) - mCRPC | Early Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 7 | 2025-03-10 | 2026-07-23 |
| Role of LncRNA H19 in The Regulation of IGF-1R Expression Blood sample collection - Hepatocellular Carcinoma, Type 2 Diabetes | Completed | Mansoura University | 101 | 2020-01-01 | 2022-04-07 | |
| A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors MM-141 - Hepatocellular Carcinoma | Phase 1 | Completed | Merrimack Pharmaceuticals | 42 | 2012-11-01 | 2016-08-04 |
| A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma OSI-906, Placebo - Adrenocortical Carcinoma | Phase 3 | Completed | Astellas Pharma Inc | 139 | 2009-12-01 | 2024-11-20 |
| A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) OSI-906, Paclitaxel - Ovarian Cancer, Solid Tumors | Phase 1 / Phase 2 | Completed | Astellas Pharma Inc | 152 | 2009-08-05 | 2024-11-20 |
| Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) BIIB022, Sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Biogen | 40 | 2009-08-01 | 2013-09-16 |
| MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646 - Non Small Cell Lung Cancer | Phase 2 | Completed | University of Kansas | 27 | 2009-06-01 | 2014-11-07 |
| QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer AMG 479, Carboplatin, Paclitaxel - Advanced Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 15 | 2009-01-01 | 2024-09-25 |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Capecitabine, Cixutumumab, Lapatinib Ditosylate - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2008-07-30 | 2020-03-24 |
| QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors AMG 479 - Askin's Tumors, Desmoplastic Small Round Cell Tumors | Phase 2 | Completed | NantCell, Inc. | 38 | 2007-10-01 | 2016-10-27 |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer Placebo, AMG 479, AMG 655 - Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NantCell, Inc. | 138 | 2007-06-01 | 2024-10-17 |
| Growth Hormone in Ischemic Heart Failure Somatropin, Placebo - Heart Failure, Systolic, Ischemic Heart Disease Chronic | Phase 3 | Completed | Göteborg University | 37 | 2004-04-28 | 2020-06-09 |
Carcinoma, Hepatocellular (3) · Graves Ophthalmopathy (3) · Neoplasms (2) · Adrenocortical Carcinoma (1) · Askin Tumor (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Heart Failure, Systolic (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Myocardial Ischemia (1) · Neoplasm Metastasis (1)
Neoplasms by Site (9) · Neoplasms (8) · Endocrine System Diseases (7) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Autoimmune Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Endocrine Gland Neoplasms (3) · Exophthalmos (3) · Eye Diseases (3) · Eye Diseases, Hereditary (3)
ganitumab (3) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · Glucocorticoids (2) · Paclitaxel (2) · Antibodies, Monoclonal (1) · BIIB022 (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Human Growth Hormone (1) · Istiratumab (1) · Lapatinib (1) · Receptor Protein-Tyrosine Kinases (1) · Sorafenib (1) · cixutumumab (1)
Shanghai Changzheng Hospital (4) · NantCell, Inc. (3) · Astellas Pharma Inc (2) · Biogen (1) · Göteborg University (1) · Mansoura University (1) · Merrimack Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · University of Kansas (1)
United States (8) · China (4) · United Kingdom (3) · Australia (2) · Canada (2) · France (2) · Italy (2) · Poland (2) · Czechia (1) · Egypt (1) · Germany (1) · Netherlands (1) · Romania (1) · Russia (1) · Singapore (1)
Ahmed Shehta, M.D. (1) · Chao H Huang, MD, FACP (1) · Chrystal Louis, MD, MPH (1) · Heba K Mohamed, M.D. (1) · Helmy Ezzat, M.D. (1) · Mohamed AA Zahran, M.D. (1) · Nora M Hussein, M.D. (1) · Noura MS Shehabeldin, M.B.B.Ch (1) · Shancheng Ren, MD,PhD (1) · Tufia C Haddad (1)
PMID 25795408, PMID 26793618, PMID 33852121
2009 (2), U10CA025224 (1), U10CA180821 (1)